Characterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity

Pharmacology Research and Perspectives

Volumn 3, Issue 1, 2015, Pages 1-14

  Higgins, Guy A ^a,b   Desnoyer, Jill ^a   Van Niekerk, Annalise ^a   Silenieks, Leo B ^a   Lau, Winnie ^a   Thevarkunnel, Sandy ^a   Izhakova, Julia ^a   Delannoy, Ines A M ^a   Fletcher, Paul J ^b,c   Delay, Josepha ^d   Dobson, Howard ^a,d,e,f  

^a InterVivo Solutions Inc   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d UNIVERSITY OF GUELPH   (Canada)

^e CanCog Technologies Incorporated   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Biomarkers; Echocardiography; Efficacy; Lorcaserin; Obesity; Safety; Valvulopathy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLOBULIN; LORCASERIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ECHOCARDIOGRAPHY; FAT CONTENT; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; ORGAN WEIGHT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; WEIGHT GAIN;

EID: 84976289336     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.84     Document Type: Article

References (49)

1. Arena Pharmaceuticals. 2010. Briefing document: NDA 22-529; Lorcaserin hydrochloride (APD356).
2. Blundell JE, Halford JCG (1998). Serotonin and appetite regulation: implications for the pharmacological treatment of obesity. CNS Drugs 9: 473-495.
3. Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA, Schölmerich J, et al. (2006). Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J Mol Endocrinol 36: 485-501.
4. Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC (2013). Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obesity Rev 14: 383-392.
5. 2C receptor agonist and d-fenfluramine on feeding patterns in the rat. Psychopharmacology 152: 256-267.
6. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. (1997). Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337: 581-588.
7. Day M, Fox GB, Marek GJ (2011). Translational medicine special issue. Biochem Pharmacol 81: 1353-1355.
8. Elangbam CS, Job LE, Zadrozny LM, Barton JC, Yoon LW, Gates LD, et al. (2008). 5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. Exp Toxicol Pathol 60: 253-262.
9. Enna SJ, Williams M (2009). Defining the role of pharmacology in the emerging world of translational research. Adv Pharmacol 57: 1-30.
10. Farrell DJ, Williams VJ (1989). Calorimetric measurements made on rats during repeated periods of weight gain and weight loss. Comp Biochem Physiol Comp Physiol 94: 61-67.
11. Fellman L, Nascimento AR, Tibirica E, Bousquet P (2013). Murine models for pharmacological studies of the metabolic syndrome. Pharmacol Ther 137: 331-340.
12. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al. (2011). A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 96: 3067-3077.
13. Flegel KM, Carroll MD, Ogden CL, Curtin LR (2010). Prevalence and trends in obesity among US adults, 1998-2008. JAMA 303: 235-241.
14. Fletcher PJ, Sinyard J, Higgins GA (2010). Genetic and pharmacological evidence that 5-HT2C receptor activation, but not inhibition, affects motivation to feed under a progressive ratio schedule of reinforcement. Pharmacol Biochem Behav 97: 170-178.
15. Ghibaudi L, Cook J, Farley C, Van Heek M, Hwa JJ (2002). Fat intake affects adiposity, comorbidity factors, and energy metabolish of Sprague-Dawley rats. Obesity Res 10: 956-963.
16. Gustafsson BI, Tømmerås K, Nordrum I, Loennechen JP, Brunsvik A, Solligård E, et al. (2005). Long-term serotonin administration induces heart valve disease in rats. Circulation 111: 1517-1522.
17. Halford JCG, Boyland EJ, Blundell JE, Kirkham TC, Harrold JA (2010). Pharmacological management of appetite expression in obesity. Nature Rev Endocrinol 6: 255-269.
18. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J (2014). Clinical development success rates for investigational drugs. Nat Biotechnol 32: 40-51.
19. Heal DJ, Gosden J, Smith SL (2009). Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br J Clin Pharmacol 68: 861-874.
20. Heal DJ, Gosden J, Smith SL (2013). A review of late stage CNS drugs for the treatment of obesity. Int J Obesity 37: 107-117.
21. Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL, et al. (2002). Activation of central melanocortin pathways by fenfluramine. Science 297: 609-611.
22. Higgins GA, Silenieks LB, Rossmann A, Rizos Z, Noble K, Soko AD, et al. (2012). The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control. Neuropsychopharmacology 37: 1177-1191.
23. 2C receptor agonists on behaviours motivated by food and nicotine and on side effect profiles. Psychopharmacology 226: 475-490.
24. Higgins GA, Sellers EM, Fletcher PJ (2013b). From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists. TIPS 34: 560-570.
25. Hutcheson JD, Setola V, Roth BL, Merryman WD (2011). Serotonin receptors and heart valve disease - it was meant 2B. Pharmacol Ther 132: 146-157.
26. Johnson DH, Flask CA, Ernsberger PR, Wong WC, Wilson DL (2008). Reproducible MRI measurement of adipose tissue volumes in genetic and dietary rodent obesity models. J Magn Reson Imaging 28: 915-927.
27. Johnson MS, Dl Smith, Nagy TR (2009). Validation of quantitative magnetic resonance (QMR) for determination of body composition in rats. Int J body Compos Res 7: 99-107.
28. Kennett GA, Clifton PG (2010). New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol Biochem Behav 97: 63-83.
29. Kola I, Landis J (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discovery 3: 711-715.
30. Leopoldo AS, Sugizaki MM, Lima-Leopoldo AP, do Nascimento AF, Luvizotto Rde A, deCampos DH, et al. (2010) Cardiac remodeling in a rat model of diet-induced obesity. Can J Cardiol 26: 423-429.
31. Levin ED, Johnson JE, Slade S, Wells C, Cauley M, Petro A, et al. (2011). Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats. J Pharmacol Exp Ther 338: 890-896.
32. Martin CK, Redman LM, Zhang J, Sanchez M, Anderson CM, Smith SR, et al. (2011). Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab 96: 837-845.
33. Nilsson C, Raun K, Yan FF, Larsen MO, Tang-Christensen M (2012). Laboratory animals as surrogate models of human obesity. Acta Pharmacol Sin 33: 173-181.
34. O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, et al. (2012). Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity 20: 1426-1436.
35. Petterino C, Argentino-Storino A (2006). Clinical chemistry and haematology historical data in control Sprague-Dawley rats from pre-clinical toxicity studies. Exp Toxicol Pathol 57: 213-219.
36. Powell AG, Apovian CM, Aronne LJ (2011). New drug targets for the treatment of obesity. Clin Pharmacol Ther 90: 40-51.
37. Schram MJ, Schoedel KA, Barlett C, Shazer RL, Anderson CM, Sellers EM (2011). Evaluation of the abuse potential evaluation of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users. Clin Pharmacol Ther 89: 683-692.
38. Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, et al. (2008). Discovery and structure-activity relationship of (1R)-8-Chloro-2, 3, 4, 5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J Med Chem 51: 305-313.
39. 2C agonist, reduces body weight in obese men and women. Obesity 17: 494-503.
40. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. (2010) Multicentre, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 263: 245-256.
41. 2C receptor activation inhibits appetitive and consummatory components of feeding and increases brain c-fos immunoreactivity in mice. Eur J Neurosci 25: 3115-3124.
42. Springer F, Machann J, Claussen CD, Schick F, Schwenzer NF (2010). Liver fat content determined by magnetic resonance imaging and spectroscopy. World J Gastroenterol 16: 1560-1566.
43. 2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 325: 577-587.
44. Thornton-Jones ZD, Kennett GA, Benwell KR, Revell DF, Misra A, Sellwood DM, et al. (2006). The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol Biochem Behav 84: 353-359.
45. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, et al. (2007). Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13.
46. Vickers SP, Clifton PG, Dourish CT, Tecott LH (1999). Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice. Psychopharmacology 143: 309-314.
47. Vickers SP, Dourish CT, Kennett GA (2001). Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology 41: 200-209.
48. Vickers SP, Jackson HC, Cheetham SC (2011). The utility of animal models to evaluate novel anti-obesity agents. Br J Pharmacol 164: 1248-1262.
49. Weissman NJ, Sanchez M, Koch GG, Smith SR, Shanahan WR, Anderson CM (2013). Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging 6: 560-567.